EE05222B1 - Triasolo(4,5-d)primidiinihendi kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine - Google Patents

Triasolo(4,5-d)primidiinihendi kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine

Info

Publication number
EE05222B1
EE05222B1 EEP200200665A EEP200200665A EE05222B1 EE 05222 B1 EE05222 B1 EE 05222B1 EE P200200665 A EEP200200665 A EE P200200665A EE P200200665 A EEP200200665 A EE P200200665A EE 05222 B1 EE05222 B1 EE 05222B1
Authority
EE
Estonia
Prior art keywords
triazolo
crystalline
preparation
amorphous form
pyrimidine compound
Prior art date
Application number
EEP200200665A
Other languages
English (en)
Estonian (et)
Inventor
Bohlin Martin
Cosgrove Steve
Lassen Bo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05222(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200665A publication Critical patent/EE200200665A/xx
Publication of EE05222B1 publication Critical patent/EE05222B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200665A 2000-06-02 2001-05-31 Triasolo(4,5-d)primidiinihendi kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine EE05222B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound
PCT/SE2001/001239 WO2001092262A1 (en) 2000-06-02 2001-05-31 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

Publications (2)

Publication Number Publication Date
EE200200665A EE200200665A (et) 2004-06-15
EE05222B1 true EE05222B1 (et) 2009-10-15

Family

ID=9892841

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200665A EE05222B1 (et) 2000-06-02 2001-05-31 Triasolo(4,5-d)primidiinihendi kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine

Country Status (36)

Country Link
US (3) US20030181469A1 (zh)
EP (3) EP2292622A1 (zh)
JP (3) JP5036947B2 (zh)
KR (1) KR100781864B1 (zh)
CN (2) CN1247583C (zh)
AR (2) AR032335A1 (zh)
AT (2) ATE320430T1 (zh)
AU (4) AU2001262874B2 (zh)
BG (3) BG65837B1 (zh)
BR (1) BR0111328A (zh)
CA (1) CA2408596C (zh)
CY (1) CY1113047T1 (zh)
CZ (2) CZ304347B6 (zh)
DE (1) DE60117972T2 (zh)
DK (2) DK1289992T3 (zh)
EE (1) EE05222B1 (zh)
ES (2) ES2259031T3 (zh)
GB (1) GB0013407D0 (zh)
HK (2) HK1052347B (zh)
HU (2) HU229374B1 (zh)
IL (4) IL152777A0 (zh)
IS (2) IS2609B (zh)
MX (1) MXPA02011795A (zh)
MY (2) MY140674A (zh)
NO (3) NO323780B1 (zh)
NZ (1) NZ522638A (zh)
PH (1) PH12011000127A1 (zh)
PL (2) PL359172A1 (zh)
PT (2) PT1493745E (zh)
RU (3) RU2325391C2 (zh)
SG (1) SG135965A1 (zh)
SI (2) SI1493745T1 (zh)
SK (1) SK287817B6 (zh)
UA (1) UA73181C2 (zh)
WO (1) WO2001092262A1 (zh)
ZA (1) ZA200209324B (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
CA2668180A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
WO2008127682A2 (en) * 2007-04-13 2008-10-23 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
ES2558843T3 (es) 2008-09-09 2016-02-09 Astrazeneca Ab Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios
US8802850B2 (en) 2009-07-27 2014-08-12 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of P2Y12 receptor
BR112012013365A2 (pt) 2009-12-03 2016-03-01 Astrazeneca Ab co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais
EP2515871B1 (en) 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
CZ303364B6 (cs) * 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
WO2012164286A1 (en) 2011-06-01 2012-12-06 Astrazeneca Ab Novel ticagrelor co - crystal
US20150329546A1 (en) * 2011-11-30 2015-11-19 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
EP2834247A4 (en) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr PREPARATION OF TICAGRELOR
WO2014000719A1 (en) * 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
US9284320B2 (en) 2012-07-04 2016-03-15 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (zh) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
EP3003276A1 (en) 2013-05-29 2016-04-13 ratiopharm GmbH Solid pharmaceutical dosage form
CN104211704B (zh) * 2013-06-03 2017-08-25 杭州领业医药科技有限公司 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (en) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
WO2015037016A2 (en) * 2013-09-10 2015-03-19 Laurus Labs Private Limited An improved process for the preparation of ticagrelor and intermediates thereof
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
WO2016024225A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
US20190002471A1 (en) * 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
CN107595790B (zh) 2016-04-21 2021-01-12 阿斯利康(瑞典)有限公司 口腔崩解片
DK3292867T3 (da) * 2016-09-09 2019-07-22 Univ Liege Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
EA202190328A1 (ru) 2018-07-27 2021-07-01 КРКА, д.д., НОВО МЕСТО Фармацевтическая композиция, содержащая тикагрелор
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AU5501598A (en) * 1996-12-20 1998-07-17 Astra Pharmaceuticals Limited Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
ES2236389T3 (es) * 1997-07-25 2005-07-16 Gilead Sciences, Inc. Composicion de analogos de nucleotidos y procedimiento de sintesis.
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound

Also Published As

Publication number Publication date
NO332306B1 (no) 2012-08-20
BG107331A (bg) 2003-07-31
AR032335A1 (es) 2003-11-05
SK16852002A3 (sk) 2003-08-05
CN1817883B (zh) 2011-10-05
BR0111328A (pt) 2003-06-10
EP1493745B2 (en) 2021-05-19
BG65837B1 (bg) 2010-02-26
SI1289992T1 (sl) 2006-08-31
EP1289992A1 (en) 2003-03-12
BG110440A (bg) 2010-03-31
ZA200209324B (en) 2004-02-16
HK1052347B (zh) 2006-09-08
NO323780B1 (no) 2007-07-02
IL152777A (en) 2008-11-26
ATE555115T1 (de) 2012-05-15
HUP0302284A3 (en) 2007-05-29
CN1817883A (zh) 2006-08-16
DK1289992T3 (da) 2006-07-03
WO2001092262A1 (en) 2001-12-06
US20070173518A1 (en) 2007-07-26
AU2010257449A1 (en) 2011-01-20
MXPA02011795A (es) 2003-04-10
US7265124B2 (en) 2007-09-04
IL202582A (en) 2012-12-31
CN1432018A (zh) 2003-07-23
HK1052347A1 (en) 2003-09-11
EP2292622A1 (en) 2011-03-09
AU2007200958A1 (en) 2007-03-29
CA2408596C (en) 2010-12-21
IL202582A0 (en) 2010-06-30
BG111017A (bg) 2011-12-30
HUP1300386A2 (en) 2003-10-28
AU2001262874B2 (en) 2007-03-22
NO20120595L (no) 2003-01-24
CZ304347B6 (cs) 2014-03-19
SK287817B6 (sk) 2011-11-04
IL152777A0 (en) 2003-06-24
CZ307468B6 (cs) 2018-09-26
US20030181469A1 (en) 2003-09-25
ATE320430T1 (de) 2006-04-15
AU6287401A (en) 2001-12-11
JP5036947B2 (ja) 2012-09-26
AR068086A2 (es) 2009-11-04
RU2010150799A (ru) 2012-06-20
CY1113047T1 (el) 2016-04-13
EP1289992B1 (en) 2006-03-15
DK1493745T3 (da) 2012-07-16
KR20030007829A (ko) 2003-01-23
AU2010257449B2 (en) 2012-03-22
PL359172A1 (en) 2004-08-23
IS3019B (is) 2020-02-15
RU2005127356A (ru) 2007-03-10
HUP0302284A2 (hu) 2003-10-28
SI1493745T1 (sl) 2012-08-31
CN1247583C (zh) 2006-03-29
IL187482A (en) 2010-06-16
GB0013407D0 (en) 2000-07-26
HK1073101A1 (en) 2005-09-23
JP5684192B2 (ja) 2015-03-11
CA2408596A1 (en) 2001-12-06
UA73181C2 (en) 2005-06-15
NO20025756D0 (no) 2002-11-29
MY148652A (en) 2013-05-15
DE60117972T2 (de) 2006-11-23
PT1493745E (pt) 2012-06-28
SG135965A1 (en) 2007-10-29
JP2012149093A (ja) 2012-08-09
PT1289992E (pt) 2006-07-31
RU2418802C2 (ru) 2011-05-20
PH12011000127A1 (en) 2016-08-31
JP2014129423A (ja) 2014-07-10
HU230471B1 (hu) 2016-07-28
ES2259031T3 (es) 2006-09-16
EP1493745B1 (en) 2012-04-25
IS8825A (is) 2009-06-02
AU2007200958B2 (en) 2010-10-07
BG66332B1 (bg) 2013-06-28
NO333289B1 (no) 2013-04-29
NO20071547L (no) 2003-01-24
PL392882A1 (pl) 2011-03-14
US20070293513A1 (en) 2007-12-20
HU229374B1 (en) 2013-11-28
NZ522638A (en) 2004-06-25
JP2003535092A (ja) 2003-11-25
DE60117972D1 (de) 2006-05-11
ES2384708T3 (es) 2012-07-11
IS6623A (is) 2002-11-15
RU2325391C2 (ru) 2008-05-27
NO20025756L (no) 2003-01-24
MY140674A (en) 2010-01-15
KR100781864B1 (ko) 2007-12-05
IS2609B (is) 2010-04-15
EE200200665A (et) 2004-06-15
EP1493745A1 (en) 2005-01-05
CZ20120293A3 (zh) 2003-07-16

Similar Documents

Publication Publication Date Title
EE05222B1 (et) Triasolo(4,5-d)primidiinihendi kristalne ja amorfne vorm, meetod selle valmistamiseks ning kasutamine
HUP0302345A3 (en) Novel triazolo pyrimidine compounds, their intermediates and process for their preparation
IL198040A0 (en) Intermediates for the preparation of triazolo (4,5-d) pyrimidine compounds
DE60336092D1 (de) Verfahren zur Herstellung substituierter Pyrimidine
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
HK1080477A1 (en) Process for the preparation of pyrimidine compounds
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20024321D0 (no) Fremgangsmåte for fremstilling av krystallinsk form I av kabergolin
NO20032731D0 (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
TW200942546A (en) A crystalline form of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one
HUP0402253A3 (en) Process for the purification of n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-phenyl]-n-ethylacetamide(zaleplon) and the preparation of its novel crystalline forms and pharmaceutical compositions containing the latters
NO20024256L (no) Fremgangsmåte for fremstilling av pyrimidonderivater med antifungal aktivitet
CA2372040A1 (en) Imidazodiazepine derivative
EE200100573A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
NO20000965L (no) FremgangsmÕte for fremstilling av veksthormon-utskillende forbindelser
AU2002229705A1 (en) Process for the preparation of saturated organic compounds
GB0110251D0 (en) Process for the preparation of pyrazolo[4,4-d]Pyrimidin-7-one compounds and intermediates thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231